BRPI1005159A2 - "método de tratamento ou prevenção de neutropenia em um paciente humano, método de tratamento ou prevenção de leucopenia em um paciente humano e método de redução da incidência de infecção" - Google Patents

"método de tratamento ou prevenção de neutropenia em um paciente humano, método de tratamento ou prevenção de leucopenia em um paciente humano e método de redução da incidência de infecção"

Info

Publication number
BRPI1005159A2
BRPI1005159A2 BRPI1005159A BRPI1005159A BRPI1005159A2 BR PI1005159 A2 BRPI1005159 A2 BR PI1005159A2 BR PI1005159 A BRPI1005159 A BR PI1005159A BR PI1005159 A BRPI1005159 A BR PI1005159A BR PI1005159 A2 BRPI1005159 A2 BR PI1005159A2
Authority
BR
Brazil
Prior art keywords
treating
human patient
preventing
incidence
infection
Prior art date
Application number
BRPI1005159A
Other languages
English (en)
Inventor
Carr Bell Adam
Benjamin Bock Jason
Herpst Jeffrey
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI1005159A2 publication Critical patent/BRPI1005159A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1005159A 2009-01-16 2010-01-15 "método de tratamento ou prevenção de neutropenia em um paciente humano, método de tratamento ou prevenção de leucopenia em um paciente humano e método de redução da incidência de infecção" BRPI1005159A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14544009P 2009-01-16 2009-01-16
US14543609P 2009-01-16 2009-01-16
PCT/US2010/021241 WO2010083439A2 (en) 2009-01-16 2010-01-15 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia

Publications (1)

Publication Number Publication Date
BRPI1005159A2 true BRPI1005159A2 (pt) 2018-04-03

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1004940A BRPI1004940A2 (pt) 2009-01-16 2010-01-15 composição farmacêutica
BRPI1005159A BRPI1005159A2 (pt) 2009-01-16 2010-01-15 "método de tratamento ou prevenção de neutropenia em um paciente humano, método de tratamento ou prevenção de leucopenia em um paciente humano e método de redução da incidência de infecção"

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI1004940A BRPI1004940A2 (pt) 2009-01-16 2010-01-15 composição farmacêutica

Country Status (16)

Country Link
US (4) US20100227818A1 (pt)
EP (2) EP2387420A2 (pt)
JP (2) JP2012515222A (pt)
KR (2) KR20110132327A (pt)
CN (2) CN102378635A (pt)
AU (2) AU2010204552B2 (pt)
BR (2) BRPI1004940A2 (pt)
CA (2) CA2749786A1 (pt)
EA (2) EA023344B1 (pt)
IL (2) IL214052A0 (pt)
MX (2) MX2011007583A (pt)
NZ (2) NZ594055A (pt)
SG (3) SG172941A1 (pt)
UA (2) UA105201C2 (pt)
WO (2) WO2010083439A2 (pt)
ZA (1) ZA201105171B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1004940A2 (pt) * 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2545411T5 (es) * 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
EP2945703A4 (en) * 2013-01-15 2016-08-31 Teva Pharma ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2018522030A (ja) * 2015-07-30 2018-08-09 エンドール テクノロジーズ, エス.エレ.Endor Technologies, S.L. 膵癌又は大腸癌の治療用コロニー刺激因子
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
EP3544658B1 (en) 2016-11-22 2024-07-03 LTS Device Technologies Ltd Apparatus for delivering a therapeutic substance
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
BR112020015758A2 (pt) * 2018-02-01 2020-12-08 Beyondspring Pharmaceuticals, Inc. Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
EP3632487B1 (en) 2018-10-05 2024-06-12 LTS Device Technologies Ltd Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) * 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
WO2021112654A1 (en) * 2019-12-05 2021-06-10 Hanmi Pharm. Co., Ltd. Methods of treating chemotherapy or radiotherapy induced neutropenia
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052712T3 (es) 1987-04-09 1994-07-16 Delta Biotechnology Ltd Vector de levadura.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2004082640A2 (en) * 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
CA2618476A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2584927C (en) * 2006-04-13 2011-02-08 Wix Filtration Corp. A body for actuating a standpipe of a replaceable filter element
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
BRPI1004940A2 (pt) * 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica

Also Published As

Publication number Publication date
US20100297062A1 (en) 2010-11-25
US8993519B2 (en) 2015-03-31
CN102378635A (zh) 2012-03-14
SG196821A1 (en) 2014-02-13
EP2387420A2 (en) 2011-11-23
IL214051A0 (en) 2011-08-31
KR20110132326A (ko) 2011-12-07
WO2010083434A3 (en) 2010-09-10
MX2011007582A (es) 2011-12-14
WO2010083439A2 (en) 2010-07-22
EA023344B1 (ru) 2016-05-31
BRPI1004940A2 (pt) 2018-06-19
JP2012515222A (ja) 2012-07-05
CN102395379A (zh) 2012-03-28
WO2010083439A3 (en) 2010-09-10
JP5753095B2 (ja) 2015-07-22
US8323634B2 (en) 2012-12-04
IL214052A0 (en) 2011-08-31
AU2010204547B2 (en) 2014-01-23
UA105201C2 (uk) 2014-04-25
US20150202268A1 (en) 2015-07-23
NZ594055A (en) 2013-03-28
US20130129669A1 (en) 2013-05-23
US20100227818A1 (en) 2010-09-09
AU2010204552B2 (en) 2014-05-01
SG172941A1 (en) 2011-08-29
KR20110132327A (ko) 2011-12-07
ZA201105171B (en) 2015-12-23
AU2010204547A1 (en) 2011-07-28
EP2387419A2 (en) 2011-11-23
WO2010083434A2 (en) 2010-07-22
SG172940A1 (en) 2011-08-29
JP2012515221A (ja) 2012-07-05
CA2749802C (en) 2016-08-23
MX2011007583A (es) 2011-12-14
NZ594056A (en) 2013-03-28
CN102395379B (zh) 2015-07-22
CA2749802A1 (en) 2010-07-22
EA201190080A1 (ru) 2014-03-31
UA103221C2 (uk) 2013-09-25
CA2749786A1 (en) 2010-07-22
EA201190079A1 (ru) 2013-02-28
AU2010204552A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
IL192198A0 (en) Skin care compositions and treatments
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
WO2009040445A3 (en) Arabinoxylo-oligosaccharides useful against gastrointestinal infections
IL187444A0 (en) Tissue treatment device and method
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
PL4066787T3 (pl) Protetyczna zastawka serca i urządzenie wprowadzające
BR112012000370A2 (pt) derivados de 1,2,4-tiazolidin-3-ona e seus usos no tratamento de câncer
BRPI0906099A2 (pt) "método de tratamento do câncer em um indivíduo"
BRPI0907102A2 (pt) composição dental, e, método para eliminar ou reduzir o desconforto e a dor associados com a hipersensibilidade da dentina
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
DE602007002740D1 (de) Trokar und Behandlungssystem
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
IL204484A (en) Expression of micro-rna in narrow peripheral blood vessels in the human body, and their uses
BRPI0922817A2 (pt) corpo médico absorvente, em particular para remoção de fluidos de feridas de cavidades do corpo humano e/ou de um animal e métodos para sua produção
BRPI0815020A2 (pt) Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.
BRPI0906047A2 (pt) "método e aparelho de tratamento de ar e sanitizalão"
BR112012009261A2 (pt) ''dispositivo de interface do paciente e método de ajuste do dispositivo de interface do paciente''
EP2493483A4 (en) TOPICAL SKIN TREATMENT FORMULATION FOR ROSACEA AND CORRESPONDING METHOD
FR2937972B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
PL2459163T3 (pl) Środek chroniący skórę, w szczególności przed hydrofobowymi (lipofilowymi) i hydrofilowymi (lipofobowymi) substancjami szkodliwymi
BRPI0811273A2 (pt) Composição anti-envelhecimento para cuidado da pele, e, método de tratamento cosmético da pele
BRPI1010785A2 (pt) "conjunto de dispositivo intramedular e método associado"
FR2948939B1 (fr) Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
BRPI0819931A2 (pt) Composições tópicas que compreendem aminoácidos não-proteogênicos e métodos de tratamento de pele

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]